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, and drug resistance develops rapidly 2 . Targeting the epigenome 3 -the chemically modified form of DNA, and of associated histones and other proteins that facilitate the packaging of DNA as chroma tin, all of which influence gene expression -is one of the alternative approaches being explored. Along with two papers 4, 5 published in Nature last year, a paper 6 on page 413 of this issue provides some insight into the potential of epigenometargeting drugs called BET inhibitors, and outlines the mechanisms by which tumours might become resistant to these drugs.
It has long been recognized 7 that tumour cells have distinct epigenomic features, which can lead to the overproduction of cancer promoting transcription factors such as MYC. Transcription factors are challenging thera peutic targets, because they lack structures that can be readily targeted with drugs. But developments in our understanding of the epigenomeregulating factors that influence gene expression, many of which seem to be 'druggable' , have provided a potential way to sidestep this hurdle.
Among these factors is the bromodomain protein family, which includes the BET subfamily 8 (BRD2, 3, 4 and T). BET proteins contain two bromodomains, each with small pockets. These pockets bind to histones that have been tagged with acetyl groups, enabling BET proteins to recruit the cell's transcriptional machinery to specific sites in the genome to regulate gene expression. BET subfamily mem bers such as BRD4, which can regulate MYC gene transcription, have been implicated in various tumours (particularly in cancers of the blood) and are therefore candidate targets for therapy 8 .
A few years ago, the first of several small molecule BET inhibitors (JQ1) was discovered, and shown 8 to effectively disrupt cancercell proliferation. This effect seemed to reflect inhibition of BETmediated regulation of MYC expression. Early clinical trials of BET inhibi tors in leukaemia and lymphoma have been encouraging. Investigators are now seeking other disease contexts in which these inhibitors might work, and predicting the acquired resist ance mechanisms that will inevitably arise.
The two 2015 studies 4,5 converge on a potential mechanism of resistance to BET inhibition in acute myelogenous leukaemia (AML). In the first, Rathert et al. 4 screened mouse AML cells for chromatinmodifying factors that are required for AMLcell sur vival. They confirmed that AML cells need Brd4, and identified several other factors for which inhibition confers AMLcell resistance to JQ1. In AML cells that were JQ1resistant, the authors observed changes in specific epi genome features in DNA enhancer regions, abundant precipitation is required to provide an effective solution to the geodynamo energy crisis. Much of the uncertainty derives from the experimental estimates of element parti tioning between iron and silicate, particularly at high temperature. For example, the present work used information from a single set of experiments to derive magnesium's solubility 8 
.
More work is clearly required to address these uncertainties, but the potential contribution of magnesium precipitation to the geodynamo provides plenty of motivation to improve our current knowledge.
Magnesium precipitation would produce a buoyant solid that rises to the top of the core 10 . The dense, ironrich residual fluid would also contribute to vigorous convection, offering ample energy for the geodynamo at relatively modest cooling rates. Such low cooling rates would allow warm fluid to accumulate at the top of the core, although convection due to magnesium precipitation might mix this warm fluid back to the core's interior. Further complications are suggested by experimental evidence 9 that the core's liquid is not saturated with oxygen and silicon, indicating that these elements might transfer into the core from the mantle. The potential for twoway transfer across the core-mantle boundary in the light of O'Rourke and Stevenson's theory is likely to send Earth scientists back to the drawing board. ■ 4 and Fong et al. 5 report that, in acute myelogenous leukaemia (AML), drug resistance is conferred by activation of the Wntsignalling pathway, which leads to DNA binding and MYC activation by the protein βcatenin. By contrast, Shu et al. 6 find that resistance in triplenegative breast cancer (TNBC) arises owing to activation of the casein kinase 2 (CK2) enzyme. CK2 phosphorylates (P) BRD4, allowing BRD4 to bind to the transcriptional regulator protein MED1 to activate MYC.
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California 94720-4767, USA. e-mail: bbuffett@berkeley.edu which regulate gene expression. These changes meant that MYC gene expression could be acti vated without Brd4.
Rathert et al. also found that genes associated with the Wntsignalling pathway, a known driver of tumour development, were upregu lated in resistant cells. Wnt activation was sufficient to promote JQ1 resistance, possi bly by driving the transcription of MYC at an enhancer generated specifically in the resist ant cells (Fig. 1) . Finally, the authors found the same mechanism of resistance to JQ1 in some other cancer types and in blood cells taken from people with leukaemia. Together, their data suggest that the usefulness of BET inhibi tors could be expanded by combining them with Wntpathway inhibitors.
Taking a different approach, Fong et al. 5 rendered mouse AML cells resistant to BET inhibition by continuously exposing these cells to another BET inhibitor, eventually yielding drugresistant clonal populations. This experi ment also showed that Wnt activation has a role in drug resistance. Furthermore, the resistant cells had features of stem cells, suggesting that the AML cancerstemcell population, or a sub set thereof, does not respond to BET inhibitors. The Wnt pathway has previously been shown to be involved in drug resistance in AML cancer stem cells 9 . Moreover, the drug resistant nature of cancer stem cells is well established 10 . However, Rathert and colleagues did not find evidence that the resistant AML cells had stemcell features -a distinction between the two reports.
In the current study, Shu et al. 6 explored BET inhibition in human breast cancer. By profiling a panel of breastcancer cell lines, they observed that one cancer subtype -'triplenegative' breast cancer -was sensitive to BET inhibition. Like Fong et al., the authors modelled acquired resistance to BET inhibi tion by culturing sensitive triplenegative cells in JQ1, and then characterized emergent resist ant cells. Resistant cells remained dependent on BRD4, but this dependence did not involve the protein's bromodomains.
A widely active transcriptional regulator protein called MED1 bound more tightly to BRD4 in resistant cells than in sensitive cells. The authors attributed this tighter binding to increased BRD4 phosphorylation mediated by the enzyme casein kinase 2 (CK2). The bind ing gave rise to bromodomainindependent, BRD4mediated transcriptional activation of MYC, among other genes (Fig. 1) . These data suggest that using a combination of CK2 and BET inhibitors to treat triplenegative breast cancer might prevent drug resistance.
Although many previous studies have demonstrated the efficacy of drugs against triplenegative breast cancer in animal and cellbased models, it is worth noting that these drugs have so far failed to combat tumours in people. As such, optimism should be tempered.
Collectively, these three reports show that BET inhibitors might have a broader potential than had previously been realized. They also highlight the possibility that BET inhibitors could be used in combination with other drugs to overcome both innate and acquired drug resistance. Although the reported resist ance mechanisms seem to reflect an adaptation to drug pressure, the root cause of resistance remains unknown. Does a specific mutation cause Wnt or CK2 activation, or are these adaptive changes that drive resistance through reversible epigenetic mechanisms? A com plete mechanistic understanding of resistance remains to be defined.
It is important to note that clinical inhibi tors of Wnt or CK2 have yet to be developed. Therefore, the hypotheses that emerge from these studies cannot be tested in the clinic. Nonetheless, these three reports provide a good foundation on which to build a better 
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A global picture of melioidosis
Comprehensive mapping and modelling have estimated global deaths from the bacterial disease melioidosis to be comparable to deaths from measles and substantially greater than those from dengue or leptospirosis.
B A R T J . C U R R I E & M I R J A M K A E ST L I
T he bacterium Burkholderia pseudomallei is found in soil and water and causes the disease melioidosis in humans and animals. It was upgraded to a Tier 1 Select Agent by the US Centers for Dis ease Control and Prevention in 2012 -the designation given to pathogens considered of highest risk. This concern is based on a mor tality rate of up to 40%, the fact that B. pseudomallei can be easily aerosolized in laboratory studies, its intrinsic resistance to standard antimicrobial agents and the lack of a vaccine. Writing in Nature Microbiology, Limmathurot sakul et al. 1 compile global literature on cases of melioidosis in humans and animals, and on the environmental presence of B. pseudomallei. The authors combine these data with environ mental and demographic parameters in a modelling framework to predict countries in which melioidosis is probably endemic, and to estimate the global burden of the disease.
Melioidosis was first described in 1912 as a septicaemic disease in morphine addicts in Yangon, Myanmar. It is now recognized as a major cause of fatal pneumonia and sepsis in Thailand, Malaysia, Singapore and northern Australia 2 . Limmathurotsakul et al. report that melioidosis is, in fact, known to be endemic in 48 countries spanning the tropics and including nations in East and South Asia, the Middle East, Africa, Latin America, the Carib bean and the Pacific. Furthermore, the authors' modelling suggests that melioidosis is severely underreported in most of these countries and is probably endemic in another 34 countries that so far have had no confirmed cases.
The authors' estimate for total global human cases for 2015 was 165,000 (a 95% credible interval of 68,000-412,000), with 89,000 deaths (95% credible interval 36,000-227,000). As the authors point out, the global mortal ity estimates are comparable to those due to measles and much higher than those due to leptospirosis and dengue infection. That melioidosis is so badly underdiagnosed is not surprising, because most cases occur in resourcepoor countries that have large rural populations and limited or no capacity for microbiological laboratory diagnosis -most crucially, the ability to culture blood samples and identify recovered bacteria.
Limmathurotsakul and colleagues' comprehensive investigation resulted in a database of 22,338 geographically located records of cases of human and animal meli oidosis and the presence of environmental B. pseudo mallei, reported between 1910 and 2014. The listing of 48 endemic countries is
